Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and lla formation and on thrombelastometry profiles

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 1, 2009, Pages 71-77

  Cvirn, Gerhard ^a   Wagner, Thomas ^a   Juergens, Guenther ^a   Koestenberger, Martin ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Endogenous fxa and flla formation; Low molecular weight heparin; Thrombelastometry; Unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11A; CHROMOGENIC SUBSTRATE; COLLAGEN; ENOXAPARIN; HEPARIN; NADROPARIN; THROMBOPLASTIN;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE POOR PLASMA; THROMBOELASTOGRAPHY;

ADULT; ENOXAPARIN; FACTOR XA; HEPARIN; HUMANS; MALE; NADROPARIN; PROTHROMBIN; REFERENCE VALUES; THROMBELASTOGRAPHY; YOUNG ADULT;

EID: 58849135706     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32831d0f80     Document Type: Article

References (25)

1. Nowak-Göttl U, Bidlingmaier C, Krümpel A, Göttl L, Kenet G. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants, and children. Br J Pharmacol 2008; 153: 1120-1127.
2. Hirsh J, Levine M. Low molecular weight heparin. Blood 1992; 79: 1 - 17.
3. Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: meta-analysis. Thromb Haemost 2001; 86: 980-984.
4. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Sem Thromb Hemost 2000; 26: 31 - 38.
5. Hofmann S, Knoefler R, Lorenz N, Siegert G, Wendisch J, Kueller D, et al. Clinical experiences with low-molecular weight heparins in pediatric patients. Thromb Res 2001; 103: 345-353.
6. Konstantinidis K, Gerasimidis T, Verdy E, Elalamy I, Samama MM, Gerotziafas GT. Inhibition of clot formation process by treatment with low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. Thromb Haemost 2007; 97: 109-118.
7. Baba L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-FXa, anti-Flla activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999; 104: 230-240.
8. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry 1991; 30: 10363-10370.
9. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1: 1504-1514.
10. Cvirn G, Gallistl S, Leschnik B, Jürgens G, Muntean W. Elevated thrombin-forming capacity of tissue factor-activated cord compared to adult plasma. J Thromb Haemost 2003; 1: 1785-1790.
11. Cvirn G, Gallistl S, Kutschera J, Wagner T, Ferstl U, Jurgens G, Koestenberger M. Collagen/endogenous thrombin-induced platelet aggregation in whole blood samples. Blood Coagul Fibrinolysis 2007; 18: 585-588.
12. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vase Biol 2006; 26: 31 -38.
13. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the fullterm infant. Blood 1987; 70: 165-170.
14. Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17.
15. Al Dieri R, Wagenvoord R, van Dedem GW, Beguin S, Hemker HC. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif: the C-domain. J Thromb Haemost 2003; 1: 907-914.
16. Cvirn G, Gallistl S, Leschnik B, Muntean W. Low tissue factor pathway inhibitor together with low antithrombin allows sufficient thrombin generation in neonates. J Thromb Haemost 2003; 1: 263-268.
17. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551 -558.
18. Mismetti P, Laporte-Simitsidis S, Navarro C, Sie P, d'Azemar P, Necciari J, et al. Aging and venous thromboembolism influence the pharmacodynamics of the antifactor Xa and antithrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998; 79: 1162-1165.
19. Gerotziafas GT, Depasse F, Chakroun T, Van Dreden P, Samama MM, Elalamy I. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma Blood Coagul Fibrinolysis 2004; 15: 149-156.
20. Koestenberger M, Gallistl S, Cvirn G, Roschitz B, Petritsch M, Leschnik B, Muntean W. Combined effects of eptifibatide and anticoagulants: differences between LMWH and UH or rH in thrombin generation inhibition but not in platelet aggregation inhibition. Thromb Haemost 2002; 88:1012-1019.
21. Bick RL, Fareed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clin Appl Thromb Haemost 1999; 5: S63-S66.
22. Lindahl AK, Abildgaard U, Larsen ML, Staalesen R, Hammer AK, Sandset PM, et al. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thromb Res 1991; 62: 607-614.
23. Audu P, Nielsen VG, Armstead V, Powell G, Kim J, Kim L, Mehta M. The impact of tissue factor pathway inhibitor on the coagulation kinetics determined by thrombelastometry. Anesth Analg 2006; 103: 841 -845.
24. Gitel SN, Medina VM, Wessler S. Inhibition of human activated Factor X by antithrombin III and alpha 1 -proteinase inhibitor in human plasma. J Biol Chem 1984; 259: 6890-6895.
25. Fuchs HE, Pizzo SV. Regulation of factor Xa in vitro in human and mouse plasma and in vivo in mouse: role of the endothelium and plasma proteinase inhibitors. J Clin Invest 1983; 72: 204 - 12049.